Acuitas: noun, insight, perception, sharpness.

Thomas D. Madden Ph.D. President and Chief Executive Officer

tom-madden-acuitasDr. Madden obtained his BSc. and Ph.D. in Biochemistry from the University of London, U.K. He has held senior academic and industry positions including Assistant Professor in Pharmacology at the University of British Columbia and Senior Director, Technology Development and Licensing at Tekmira Pharmaceuticals. At Tekmira Pharmaceuticals Dr. Madden was responsible for product development of several liposomal anticancer agents including Marqibo™ (liposomal vincristine). Dr. Madden founded Acuitas Therapeutics in February 2009 and through his role as President and CEO has guided the company in its corporate relationships. The collaboration he established with Alnylam Pharmaceuticals resulted in development of key delivery technology that has been translated into two RNAi therapeutics in clinical development. Dr. Madden has over 50 publications relating to LNP technology and development of pharmaceutical products.

Our History

Acuitas Therapeutics is a private company incorporated in British Columbia, Canada. We were founded in February 2009 (initially as AlCana Technologies) and have partnered with Alnylam Pharmaceuticals, the University of British Columbia, IRAP and others on several research and development programs relating to systemic delivery of nucleic acid therapeutics.
Contact Information

Twitter Feed

Find out what's happening, right now, with Acuitas Therapeutics.


Copyright 2018 Acuitas Therapeutics. Web Design by Tommy Le Inc.